WO2011130788A1 - Combined method for improving the health of skin - Google Patents

Combined method for improving the health of skin Download PDF

Info

Publication number
WO2011130788A1
WO2011130788A1 PCT/AU2011/000452 AU2011000452W WO2011130788A1 WO 2011130788 A1 WO2011130788 A1 WO 2011130788A1 AU 2011000452 W AU2011000452 W AU 2011000452W WO 2011130788 A1 WO2011130788 A1 WO 2011130788A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
amount
topical composition
extract
vitamin
Prior art date
Application number
PCT/AU2011/000452
Other languages
French (fr)
Inventor
Amie Skilton
Original Assignee
Fit-Bioceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010901652A external-priority patent/AU2010901652A0/en
Application filed by Fit-Bioceuticals Pty Ltd filed Critical Fit-Bioceuticals Pty Ltd
Priority to AU2011242403A priority Critical patent/AU2011242403A1/en
Publication of WO2011130788A1 publication Critical patent/WO2011130788A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/62—Nymphaeaceae (Water-lily family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/88—Two- or multipart kits
    • A61K2800/884—Sequential application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Definitions

  • the present invention relates to a method for improving the health of the skin of a subject by administration of a combination of oral and topical compositions.
  • compositions that can improve the health of skin by targeting the skin from the exterior and from within.
  • compositions improve the health of skin by providing topical compositions which act on the exterior of the skin and an oral composition that acts from within by improving the nutritional health of an individual.
  • the present invention provides a method for improving the health of the skin of a subject, the method comprising administering to a subject an oral composition comprising resveratrol, a proanthocyanidin, grape skin extract and vitamin C; a first topical composition comprising glycolic acid, a Vibrio Alginolyticus ferment filtrate and a water lily extract; and a second topical composition comprising a yeast extract, essential fatty acids, moisturiser, a water lily extract, water-soluble vitamins and fat-soluble vitamins.
  • the first topical composition is administered to the skin before the second topical composition.
  • the first topical composition may be left on the skin for approximately 10 min and then removed.
  • the grape skin extract may be obtained from Vitis vinifera.
  • the amount of grape skin extract present in the oral composition may be between about 10 mg and about 200 mg. In one embodiment the amount of grape skin extract present in the oral composition is about 30 mg.
  • the amount of resveratrol present in the oral composition may be between about 25 mg and about 300 mg. In one embodiment the amount of resveratrol present in the oral composition is about 100 mg.
  • the resveratrol may be present in the oral composition as an extract.
  • the extract may be obtained from Polygonum cuspidatum or Polygonum sachalinense.
  • the amount of the proanthocyanidin present in the oral composition may be between about 15 mg and about 80 mg. In one embodiment the amount of the proanthocyanidin present in the oral composition is about 47.5 mg.
  • the proanthocyanidin may be present in the oral composition as an extract.
  • the extract may be obtained from grape seed.
  • the grape may be Vitis vinifera.
  • the amount of vitamin C present in the oral composition may be between about 25 mg and about 200 mg. In one embodiment the amount of vitamin C present in the oral composition is about 50 mg.
  • the oral composition may further comprise quercetin.
  • the amount of quercetin present in the oral composition may be between about 10 mg and about 100 mg. In one embodiment the amount of quercetin present in the oral composition is about 40 mg.
  • the oral composition may further comprise one or more pharmaceutically acceptable excipients, diluents or adjuvants.
  • the oral composition may be in the form of a unit dosage form, for example tablets, capsules or caplets.
  • the method may involve oral administration of between 1 and 5 dosage forms per day.
  • the oral composition may be in the form of a food stuff or beverage.
  • the amount of glycolic acid in the first topical composition may be between about 10% w/w and about 20% w/w. In one embodiment the amount of glycolic acid in the first topical composition is about 15% w/w.
  • the amount of Vibrio Aiginolyticus ferment filtrate in the first topical composition may be between about 1% w/w and about 5% w/w. In one embodiment the amount of Vibrio Aiginolyticus ferment filtrate present in the first topical composition may be about 1.5% w/w.
  • the amount of water lily extract in the first topical composition may be about 3% w/w.
  • the water lily extract in the first topical composition may be obtained from Nymphaea alba.
  • the amount of yeast extract in the second topical composition may be between about 1 % w/w and about 15% w/w. In one embodiment the amount of yeast extract in the second topical composition may be 5% w/w.
  • the yeast extract in the second topical composition may be obtained from a species of Saccharomyces.
  • the species may be Saccharomyces cerevisiae.
  • the amount of essential fatty acids in the second topical composition may be about 0.2% w/w.
  • the essential fatty acids in the second topical composition may be derived from a marine source.
  • the essential fatty acids may comprise eicosapentaenoic acid and docosahexaenoic acid.
  • the amount of moisturiser present in the second topical composition may be between about 0.5% w/w and about 7% w/w. In one embodiment the amount of moisturiser present in the second topical composition is 1.5% w/w.
  • the moisturiser may be obtained from Sefa vulgaris, typically from the root of Beta vulgaris.
  • the amount of water lily extract in the second topical composition may be about 3% w/w.
  • the water lily extract in the second topical composition may be obtained from Nymphaea alba.
  • the amount of fat-soluble vitamins present in the second topical composition may be between about 0.1% w/w and about 5% w/w. In one embodiment the amount of fat-soluble vitamins present in the second topical composition may be between about 0.5% w/w and about 2% w/w.
  • the fat- soluble vitamins may comprise vitamin E, vitamin Ki and vitamin A. .
  • the amount of water-soluble vitamins present in the second topical composition may be between about 0.1% w/w and about 5% w/w. In one embodiment the amount of water-soluble vitamins present in the second topical composition may be between about 0.5% w/w and about 3% w/w.
  • the water-soluble vitamins may comprise vitamin C, vitamin B3, vitamin B5 and vitamin B6.
  • an element means one element or more than one element.
  • proanthocyanidin refers to flavanol compounds, and in particular oligomers comprising at least one flavanol moiety.
  • proanthocyanidins include catechins, such as epigaliocatechin 3-gallate (EGCG).
  • extract refers to an active preparation derived from one or more plants.
  • active means that the extract is capable of producing a desired therapeutic or cosmetic benefit as disclosed herein.
  • An extract is obtained by a process of "extraction” which will be understood by those skilled in the art as, in general terms, treatment of plant material (for example, fruit, fruit skin, leaves, seed, bark, roots, stems and the like) with a solvent, a liquid, or a supercritical fluid to dissolve the active compound(s) and separate the same from residual unwanted plant material.
  • An extract may be in liquid form (for example as a decoction, solution, infusion or tincture) or solid form (for example as a powder or granules).
  • the term "pharmaceutically acceptable” means that the compound to which it refers is suitable for use in contact with tissues of the body without undue toxicity, incompatibility, instability, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio.
  • the terms “improve” and “improving” refer to the ability to achieve a measurable benefit in relation to the health of skin (such as the appearance and/or texture of the skin), or otherwise prevent, hinder, retard, or reverse the deterioration in the appearance of the skin in any way whatsoever.
  • the terms “improve”, “improving” and the like are to be considered in their broadest context.
  • “food”, “foods”, “beverage” or “beverages” includes but is not limited to health foods, functional foods and foods for specified health use.
  • the term can be used to include a feedstuff.
  • moistureturiser or “moisturisers” includes but is not limited to natural plant-derived active ingredients that support the natural moisturising factors (NMF) of the skin of a subject.
  • NMF moisturising factors
  • the present invention contemplates combination therapies, wherein the oral composition and topical compositions as disclosed herein are coadministered.
  • the oral composition and topical compositions may be administered by coadministration or sequential administration with the compositions disclosed herein.
  • coadministered is meant simultaneous administration of the oral compositions and topical compositions.
  • simultaneous administration is meant a time difference of from seconds, minutes, hours or days between the administration of the two types of the oral composition and the topical compositions agents.
  • the oral and topical compositions may be administered in any order,
  • the term, "about,” is understood to refer to a range of numbers that a person of skill in the art would consider equivalent to the recited value in the context of achieving the same function or result.
  • the term "subject” includes humans, primates, livestock animals (eg. sheep, pigs, cattle, horses, donkeys), laboratory test animals (eg. mice, rabbits, rats, guinea pigs), companion animals (eg. dogs, cats) and captive wild animals (eg. foxes, kangaroos, deer).
  • livestock animals eg. sheep, pigs, cattle, horses, donkeys
  • laboratory test animals eg. mice, rabbits, rats, guinea pigs
  • companion animals eg. dogs, cats
  • captive wild animals eg. foxes, kangaroos, deer.
  • the subject is a human or a laboratory test animal.- Even more typically, the subject is a human.
  • the present inventors have surprisingly discovered that it is possible to improve the health of the skin of a subject by administering an oral composition comprising resveratrol, a proanthocyanidin, grape skin extract and vitamin C; a first topical composition comprising glycolic acid, a - Vibrio Alginolyticus ferment filtrate and a water lily extract; and a second topical composition comprising a yeast extract, essential fatty acids, moisturiser, a water lily extract, water-soluble vitamins and fat- soluble vitamins.
  • compositions of the present invention may improve the health of the skin of a subject by providing cosmetic improvements including:
  • the first topical composition is administered to the skin before the second topical composition.
  • the first topical composition may be administered to the face and neck.
  • the first topical composition may be left on the skin for approximately 10 min and then removed.
  • the first topical composition may be left on for approximately 5 min, 6 min, 7 min, 8 min, 9 min, 11 min, 12 min, 13 min or 14 min.
  • the first topical composition may be removed with water.
  • the water may be warm.
  • a cotton pad, cotton wool or tissue or any other suitable may also be used to remove the first topical composition from the skin.
  • the second topical composition may be administered to the face and neck and may be left on the skin overnight.
  • the amount of resveratrol present in the composition may be between about 25 mg and about 300 mg, or more typically between about 25 mg and about 200 mg, or between about 50 mg and about 150 mg.
  • the composition may comprise about 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, or 145 mg of resveratrol.
  • the resveratrol may be present in the composition in a highly pure form (for example greater than 98% pure), or alternatively as part of an extract.
  • the extract may be obtained from Polygonum cuspidatum or Polygonum sachalinense, or indeed any other plant or part thereof which contains resveratrol (for example cranberries, blueberries, mulberries, raspberries and certain pine trees).
  • the resveratrol may be present in the composition in the form of a salt or derivative thereof. Suitable derivatives include compounds wherein one or more of the hydroxy groups are derivatised, for example acylated or alkylated.
  • the amount of proanthocyanidin present in the composition may be between about 15 mg and about 80 mg, or between about 25 mg and about 60 mg, or between about 35 mg and about 55 mg.
  • the composition may comprise about 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, 50 mg, 51 mg, 52 mg, 53 mg, or 54 mg of a proanthocyanidin.
  • the proanthocyanidin may be present in the composition in a highly pure form (for example greater than 98% pure), or alternatively as part of an extract.
  • the proanthocyanidin may be obtained from grape seed, for example grape seed of Vitis vinifem.
  • grape seed for example grape seed of Vitis vinifem.
  • the proanthocyanidin may also be extracted from many other plants or parts thereof, for example, apples, pine bark, cinnamon, cocoa, grape skin, bilberries, cranberries, chokeberries, blackcurrants, green tea, black tea, Quercus petraea and Quercus robur heartwood.
  • the proanthocyanidin may be present in the composition in the form of a salt or derivative thereof. Suitable derivatives include compounds wherein one or more of the hydroxy groups are derivatised, for example acylated or alkylated.
  • the amount of grape skin extract present in the composition may be between about 10 mg and about 200 mg, or between about 10 mg and about 100 mg, or between about 20 mg and about 50 mg.
  • the composition may comprise about 25 mg, 30 mg, 35 mg, 40 mg, or 45 mg of grape skin extract.
  • the grape skin extract may be obtained from any species of the Vitis genus.
  • the species may be Vitis vinifera.
  • the grape skin extract may also be obtained from other species of the Vitis genus, including but not limited to Vitis mustangensis, Vitis aestivalis, Vitis riparia, Vitis rotundifolia, and Vitis labrusca.
  • the amount of vitamin C present in the composition may be between about 25 mg and about 200 mg, or between about 25 mg and about 100 mg, or between about 35 mg and about 65 mg.
  • the composition may comprise about 40 mg, 45 mg, 50 mg, 55 mg, or 60 mg vitamin C.
  • compositions of the invention may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
  • the method may include the step of bringing the components of the oral composition into association with a carrier which constitutes one or more accessory ingredients.
  • the compositions are prepared by uniformly and intimately bringing into association the components of the oral composition with a liquid carrier or finely divided solid carrier, or both and then, if necessary, shaping the product into the desired composition.
  • compositions suitable for oral administration may be presented as discrete units (i.e. dosage forms) such as gelatine or HP C capsules, cachets or tablets, each containing a predetermined amount each component of the composition as a powder, granules, as a solution or a suspension in an aqueous liquid or a non-aqueous liquid, or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
  • dosage forms such as gelatine or HP C capsules, cachets or tablets, each containing a predetermined amount each component of the composition as a powder, granules, as a solution or a suspension in an aqueous liquid or a non-aqueous liquid, or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
  • the components of the oral composition may be formulated with one or more pharmaceutically acceptable carriers such as starch, lactose, microcrystalline cellulose and/or silicon dioxide. Additional ingredients may include lubricants such as magnesium stearate and/or calcium stearate.
  • Tablets may be prepared by compression or moulding, optionally with one or more accessory, ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the components of the oral composition in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant (for example magnesium stearate or calcium stearate), inert diluent or a surface active/dispersing agent.
  • Moulded tablets may be made by moulding a mixture of the powdered composition moistened with an inert liquid diluent, in a suitable machine.
  • the tablets may optionally be coated, for example, with an enteric coating and may be formulated so as to provide slow or controlled release of the composition therein.
  • an oral composition of the invention for any particular individual will depend upon a variety of factors including, for example, the activity of the resveratrol, proanthocyanidin, grape skin and vitamin C employed, the age, body weight, general health and diet of the individual to be treated, the time of administration, rate of excretion, and combination with any other treatment or therapy. Single or multiple daily administrations can be carried out with dose levels. A broad range of doses may be applicable.
  • the present invention contemplates the administration of the oral composition in a food or beverage.
  • the food may be a solid form or a liquid form.
  • foods or beverages include, but are not limited to soft drinks, carbonated drinks, nutritional beverages, fruit beverages, and milk beverages (including a concentrated stock solution of such a beverage and a dry powder for preparation of such a beverage); confectionery such as chewing gum and chocolate; dairy products such as milk, yogurt, butter, and cheese.
  • the amount of glycolic acid (or hydroxyacetic acid) present in the first topical composition may be between about 10% w/w and about 20% w/w, or more typically between about 12% w/w and about 18% w/w.
  • the first topical composition may comprise about 13% w/w, 14% w/w, 15% w/w, 16% w/w, or 17% w/w glycolic acid.
  • the glycolic acid may be present in the composition in a highly pure form (for example greater than 98% pure) or alternatively as part of an extract.
  • the extract may be obtained from sugarcane, sugar beets, pineapple, cantaloupe, and unripe grapes, or indeed any other plant or part thereof which glycolic acid.
  • the glycolic acid may be prepared by the reaction of chloroacetic acid with sodium hydroxide followed by re-acidification, however, a person skilled in the art will appreciate that there are other chemical synthesis with which to prepare glycolic acid.
  • Glycolic acid can also be prepared using an enzymatic biochemical process.
  • the glycolic acid may be present in the composition in the form of a salt or derivative thereof.
  • the amount of Vibrio Alginolyticus ferment filtrate present in the first topical composition may be between about 1% w/w and about 5% w/w, or between about 1 % w/w and about 3% w/w, or between about 1% w/w and about 2% w/w.
  • the composition may comprise about 1.1 % w/w, 1.2% w/w, 1.3% w/w, 1.4% w/w, 1.5% w/w, 1.6% w/w, 1 .7% w/w, 1.8% w/w or 1.9% w/w of Vibrio Alginolyticus ferment filtrate.
  • the Vibrio Alginolyticus ferment filtrate may be present in the composition in a highly pure form (for example greater than 98% pure), or alternatively as part of an extract.
  • the amount of water lily extract present in the first topical composition may be between about 1% w/w and about 5% w/w, or more typically between about 2% w/w and about 4% w/w.
  • the composition may comprise about 2.5% w/w, 3.0% w/w, or 3.5% w/w of water lily extract.
  • the water lily extract may be obtained from any species of Nymphaeaceae.
  • the species may be Nymphaea alba.
  • the extract may be derived from the flower of a species of Nymphaeaceae.
  • the water lily extract may be present in the composition in the form of a salt or derivative thereof and may be in the form of a liquid or oil.
  • the amount of yeast extract present in ' the second topical composition may be between about 1% w/w and about. 15% w/w, or more typically between about 2% w/w and about 10% w/w.
  • the second topical composition may comprise about 3% w/w, 4% w/w, 5% w/w, 6% w/w, 7% w/w, 8% w/w, or 9% w/w of yeast extract.
  • the yeast extract may be obtained from any species of Saccharomyces.
  • the species may be Saccharomyces cerevisiae.
  • the yeast extract may by a polysaccharide extracted from Saccharomyces cerevisiae.
  • the polysaccharide may be a beta-glucan.
  • the amount of essential fatty acids present in the second topical composition may be between about 0.1% w/w and about 1% w/w, or more typically between about 0.1% w/w and about 0.5% w/w.
  • the second topical composition may comprise about 0.15% w/w, 0.2% w/w, 0.25% w/w, 0.3% w/w,. 0.35% w/w, 0.4% w/w, or 0.45% w/w of essential fatty acids.
  • the essential fatty acids may be derived from a marine source.
  • the marine source may be vegetal plankton.
  • the essential fatty acids may be omega 3 polyunsaturated fatty acids, for example but not limited to eicosapentaenoic acid and docosahexaenoic acid.
  • the amount of moisturiser present in the second topical composition may be between about 0.5% w/w and about 7% w/w, or between about 0.5% w/w and about 2.5% w/w, or more typically between about 1.0% w/w and about 2.0% w/w.
  • the second topical composition may comprise about 1.1% w/w, 1.2% w/w, 1.3% w/w, 1.4% w/w, 1.5% w/w, 1.6% w/w, 1.7% w/w, 1.8% w/w or 1.9% w/w of moisturiser.
  • the moisturiser may be derived from an extract of Sefa vulgaris.
  • the extract may be from the root of Beta vulgaris.
  • the amount of water lily extract present in the second topical composition may be between about 1% w/w and about 5% w/w, or more typically between about 2% w/w and about 4% w/w.
  • the composition may comprise about 2.5% w/w, 3.0% w/w, or 3.5% w/w of water lily extract.
  • the water lily extract may be obtained from any species of Nymphaeaceae.
  • the species may be Nymphaea alba.
  • the extract may be derived from the flower of a species of Nymphaeaceae.
  • the water lily extract may be present in the composition in the form of a salt or derivative thereof and may be in the form of a liquid or oil.
  • the amount of fat-soluble vitamins present in the second topical composition may be between about 0.1% w/w and about 5% w/w, or more typically between about 0.1% w/w and about 3.5% w/w.
  • the second topical composition may comprise about 0.5% w/w, 1.0% w/w, 1.5% w/w, 2.0% w/w, 2.5% w/w or 3.0% w/w of fat-soluble vitamins.
  • the fat-soluble vitamins may comprise vitamin E, vitamin Ki and vitamin A.
  • the vitamin E may be present as tocopheryl acetate, the vitamin Ki may be present as phytonadione, and the vitamin A may be present as retinyl palmitate.
  • the fat-soluble vitamins may be present in the second topical composition in the form of other salt or derivative thereof.
  • the amount of water-soluble vitamins present in the second topical composition may be between about 0.1% w/w and about 5% w/w, or more typically between about 0.1% w/w and about 3.5% w/w.
  • the second topical composition may comprise about 0.5% w/w, 1.0% w/w, 1.5% w/w, 2.0% w/w, 2.5% w/w or 3.0% w/w of water-soluble vitamins.
  • the water-soluble vitamins may comprise vitamin C, vitamin B3, vitamin B5 and vitamin B6.
  • the vitamin C may be present as sodium ascorbyl phosphate
  • the vitamin B3 may be present as niacinamide
  • the vitamin B5 may be present as calcium pantothenate
  • the vitamin B6 may be present as pyndoxine hydrochloride.
  • the water-soluble vitamins may be present in the second topical composition in the form of other salt or derivative thereof.
  • topical formulations of the present invention typically comprise the components of the invention together with one or more acceptable carriers, and optionally any other therapeutic ingredients.
  • Formulations suitable for topical administration may be in any suitable form, formulated for example as liminents, lotions, creams, . gels, ointments or pastes.
  • Examples of pharmaceutically acceptable carriers or diluents are demineralised or distilled water; saline solution; vegetable based oils such as peanut oil, safflower oil, olive oil, cottonseed oil, maize oil, sesame oil, arachis oil or coconut oil; silicone oils, including polysiloxanes, such as methyl polysiloxane, phenyl polysiloxane and methylphenyl polysolpoxane; volatile silicones; mineral oils such as liquid paraffin, soft paraffin or squalane; cellulose derivatives such as methyl cellulose, ethyl cellulose, carboxymethylcellulose, sodium carboxymethylcellulose or hydroxypropylmethylcellulose; lower alkanols, for example ethanol or iso-propanol; lower aralkanols; lower polyalkylene glycols or lower alkylene glycols, for example polyethylene glycol, polypropylene glycol, ethylene glycol, propylene glycol, 1 ,3-butylene
  • Lotions according to the present invention include those suitable for application to the skin.
  • Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturiser such as glycerol, or oil such as castor oil or arachis oil.
  • an agent to hasten drying and to cool the skin such as an alcohol or acetone, and/or a moisturiser such as glycerol, or oil such as castor oil or arachis oil.
  • Creams, ointments or pastes according to the present invention are semi-solid formulations of the agents for external application. They may be made by mixing the components in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with a . greasy or non-greasy basis.
  • the basis may comprise hydrocarbons such as hard, soft or liquid glycerin, paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as corn, arachis, castor or olive oil; wool fat or its derivatives, or a fatty acid such as stearic or oleic acid together with an alcohol such as propylene glycol or macrogols.
  • compositions for use in accordance with the invention are outlined below.
  • the following is to be construed as merely an illustrative example of a composition and not as a limitation of the scope of the present invention in any way.
  • a typical composition for oral administration is outlined below:
  • Each capsule or tablet comprises:
  • vitamin C Ascorbic acid 50 mg
  • Dosage 1 capsule or tablet once to three times daily.
  • a typical first composition for topical administration is outlined below:
  • a thin layer of the first topical composition is administered to the skin and left for 10 mins.
  • the first topical composition is then removed with warm water.
  • a typical second composition for topical administration is outlined below:
  • Beta Vulgaris root extract 1.5%w/w
  • vitamin E vitamin Ki & vitamin A
  • vitamin C vitamin B3, vitamin B5 & vitamin B6 0.5-3%
  • a thin layer of the second topical composition is administered to the skin and left on overnight.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods for improving the health of the skin of a subject comprising administering an oral composition comprising resveratrol, a proanthocyanidin, grape skin extract and vitamin C; a first topical composition comprising glycolic acid, a Vibrio Alginolyticus ferment filtrate and a water lily extract; and a second topical composition comprising a yeast extract, essential fatty acids, moisturiser, a water lily extract, water-soluble vitamins and fat-soluble vitamins are described.

Description

Combined method for improving the health of skin
Field of the Invention
The present invention relates to a method for improving the health of the skin of a subject by administration of a combination of oral and topical compositions.
Background of the Invention
Many people wish to improve the visual appearance of their skin and a great deal of research is . devoted to means of achieving such improvements. Most of the commercially available products address the problem of improving the health of skin by the topical application of a composition, in other words by acting on the exterior of the skin. However, such topical applications can at best only penetrate several layers of skin and ultimately cannot reach or penetrate the dermoepidermal junction and therefore the effects of topical compositions are limited. Accordingly, there is a need for compositions that can improve the health of skin by targeting the skin from the exterior and from within.
The present inventors have surprisingly found that combinations of oral and topical compositions improve the health of skin by providing topical compositions which act on the exterior of the skin and an oral composition that acts from within by improving the nutritional health of an individual.
Summary of the Invention
In a first aspect, the present invention provides a method for improving the health of the skin of a subject, the method comprising administering to a subject an oral composition comprising resveratrol, a proanthocyanidin, grape skin extract and vitamin C; a first topical composition comprising glycolic acid, a Vibrio Alginolyticus ferment filtrate and a water lily extract; and a second topical composition comprising a yeast extract, essential fatty acids, moisturiser, a water lily extract, water-soluble vitamins and fat-soluble vitamins.
In one embodiment the first topical composition is administered to the skin before the second topical composition. The first topical composition may be left on the skin for approximately 10 min and then removed.
The grape skin extract may be obtained from Vitis vinifera. The amount of grape skin extract present in the oral composition may be between about 10 mg and about 200 mg. In one embodiment the amount of grape skin extract present in the oral composition is about 30 mg.
The amount of resveratrol present in the oral composition may be between about 25 mg and about 300 mg. In one embodiment the amount of resveratrol present in the oral composition is about 100 mg.
The resveratrol may be present in the oral composition as an extract. The extract may be obtained from Polygonum cuspidatum or Polygonum sachalinense.
The amount of the proanthocyanidin present in the oral composition may be between about 15 mg and about 80 mg. In one embodiment the amount of the proanthocyanidin present in the oral composition is about 47.5 mg.
The proanthocyanidin may be present in the oral composition as an extract. The extract may be obtained from grape seed. The grape may be Vitis vinifera.
The amount of vitamin C present in the oral composition may be between about 25 mg and about 200 mg. In one embodiment the amount of vitamin C present in the oral composition is about 50 mg.
The oral composition may further comprise quercetin. The amount of quercetin present in the oral composition may be between about 10 mg and about 100 mg. In one embodiment the amount of quercetin present in the oral composition is about 40 mg.
The oral composition may further comprise one or more pharmaceutically acceptable excipients, diluents or adjuvants.
The oral composition may be in the form of a unit dosage form, for example tablets, capsules or caplets.
The method may involve oral administration of between 1 and 5 dosage forms per day. The oral composition may be in the form of a food stuff or beverage. The amount of glycolic acid in the first topical composition may be between about 10% w/w and about 20% w/w. In one embodiment the amount of glycolic acid in the first topical composition is about 15% w/w.
The amount of Vibrio Aiginolyticus ferment filtrate in the first topical composition may be between about 1% w/w and about 5% w/w. In one embodiment the amount of Vibrio Aiginolyticus ferment filtrate present in the first topical composition may be about 1.5% w/w.
The amount of water lily extract in the first topical composition may be about 3% w/w.
The water lily extract in the first topical composition may be obtained from Nymphaea alba.
The amount of yeast extract in the second topical composition may be between about 1 % w/w and about 15% w/w. In one embodiment the amount of yeast extract in the second topical composition may be 5% w/w.
The yeast extract in the second topical composition may be obtained from a species of Saccharomyces. The species may be Saccharomyces cerevisiae.
The amount of essential fatty acids in the second topical composition ma be about 0.2% w/w.
The essential fatty acids in the second topical composition may be derived from a marine source. In one embodiment the essential fatty acids may comprise eicosapentaenoic acid and docosahexaenoic acid.
The amount of moisturiser present in the second topical composition may be between about 0.5% w/w and about 7% w/w. In one embodiment the amount of moisturiser present in the second topical composition is 1.5% w/w. The moisturiser may be obtained from Sefa vulgaris, typically from the root of Beta vulgaris.
The amount of water lily extract in the second topical composition may be about 3% w/w. The water lily extract in the second topical composition may be obtained from Nymphaea alba. The amount of fat-soluble vitamins present in the second topical composition may be between about 0.1% w/w and about 5% w/w. In one embodiment the amount of fat-soluble vitamins present in the second topical composition may be between about 0.5% w/w and about 2% w/w. The fat- soluble vitamins may comprise vitamin E, vitamin Ki and vitamin A. .
The amount of water-soluble vitamins present in the second topical composition may be between about 0.1% w/w and about 5% w/w. In one embodiment the amount of water-soluble vitamins present in the second topical composition may be between about 0.5% w/w and about 3% w/w. The water-soluble vitamins may comprise vitamin C, vitamin B3, vitamin B5 and vitamin B6.
Definitions
Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
In the context of this specification, the terms "a" and "an" are used herein to refer to one or to more than one (i.e. to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.
In the context of this specification, the term "proanthocyanidin" refers to flavanol compounds, and in particular oligomers comprising at least one flavanol moiety. Examples of proanthocyanidins include catechins, such as epigaliocatechin 3-gallate (EGCG).
In the context of this specification, the term "extract" refers to an active preparation derived from one or more plants. In the context of this specification "active" means that the extract is capable of producing a desired therapeutic or cosmetic benefit as disclosed herein. An extract is obtained by a process of "extraction" which will be understood by those skilled in the art as, in general terms, treatment of plant material (for example, fruit, fruit skin, leaves, seed, bark, roots, stems and the like) with a solvent, a liquid, or a supercritical fluid to dissolve the active compound(s) and separate the same from residual unwanted plant material. An extract may be in liquid form (for example as a decoction, solution, infusion or tincture) or solid form (for example as a powder or granules). In the context of this specification, the term "pharmaceutically acceptable" means that the compound to which it refers is suitable for use in contact with tissues of the body without undue toxicity, incompatibility, instability, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio.
In the context of this specification, the terms "improve" and "improving" refer to the ability to achieve a measurable benefit in relation to the health of skin (such as the appearance and/or texture of the skin), or otherwise prevent, hinder, retard, or reverse the deterioration in the appearance of the skin in any way whatsoever. Thus the terms "improve", "improving" and the like are to be considered in their broadest context.
In the context of this specification, "food", "foods", "beverage" or "beverages" includes but is not limited to health foods, functional foods and foods for specified health use. When such food or beverage of the present invention is used for subjects other than humans, the term can be used to include a feedstuff.
In the context of this specification "moisturiser" or "moisturisers" includes but is not limited to natural plant-derived active ingredients that support the natural moisturising factors (NMF) of the skin of a subject.
The present invention contemplates combination therapies, wherein the oral composition and topical compositions as disclosed herein are coadministered. For example, the oral composition and topical compositions may be administered by coadministration or sequential administration with the compositions disclosed herein. By "coadministered" is meant simultaneous administration of the oral compositions and topical compositions. By "sequential" administration is meant a time difference of from seconds, minutes, hours or days between the administration of the two types of the oral composition and the topical compositions agents. The oral and topical compositions may be administered in any order,
In the context of this specification, the term, "about," is understood to refer to a range of numbers that a person of skill in the art would consider equivalent to the recited value in the context of achieving the same function or result. In the context of this specification, the term "subject" includes humans, primates, livestock animals (eg. sheep, pigs, cattle, horses, donkeys), laboratory test animals (eg. mice, rabbits, rats, guinea pigs), companion animals (eg. dogs, cats) and captive wild animals (eg. foxes, kangaroos, deer). Typically, the subject is a human or a laboratory test animal.- Even more typically, the subject is a human.
Detailed Description of the Invention
The present inventors have surprisingly discovered that it is possible to improve the health of the skin of a subject by administering an oral composition comprising resveratrol, a proanthocyanidin, grape skin extract and vitamin C; a first topical composition comprising glycolic acid, a - Vibrio Alginolyticus ferment filtrate and a water lily extract; and a second topical composition comprising a yeast extract, essential fatty acids, moisturiser, a water lily extract, water-soluble vitamins and fat- soluble vitamins.
The administration of a combination of the oral composition and the first and second topical compositions of the present invention may improve the health of the skin of a subject by providing cosmetic improvements including:
- anti-ageing effects
- retardation and reduction of wrinkles or visible lines
- improved skin texture and firmness
- protection against oxidative stress
- promotion of collagen production
- promotion of elastin production
- skin lightening effects
- promotion of skin repair
- improvement in collagen cross-linking
- supporting the skin barrier function
- increasing skin radiance
- reduction of acne scars
- reduction of age spots
- promotion of skin regeneration
- promotion of desquamation
- restoration of the hydrolipid film
- promotion of lipid synthesis - promotion of skin healing
- restoration of the physiological balance of the skin
- reduction of inflammation of skin
- promotion of cell renewal
- increasing of natural moisturising factors in the skin
In accordance with particular embodiments of the invention the first topical composition is administered to the skin before the second topical composition. The first topical composition may be administered to the face and neck. The first topical composition may be left on the skin for approximately 10 min and then removed. Alternatively the first topical composition may be left on for approximately 5 min, 6 min, 7 min, 8 min, 9 min, 11 min, 12 min, 13 min or 14 min. The first topical composition may be removed with water. The water may be warm. A cotton pad, cotton wool or tissue or any other suitable may also be used to remove the first topical composition from the skin. The second topical composition may be administered to the face and neck and may be left on the skin overnight.
In accordance with particular embodiments of the invention the amount of resveratrol present in the composition may be between about 25 mg and about 300 mg, or more typically between about 25 mg and about 200 mg, or between about 50 mg and about 150 mg. Alternatively, the composition may comprise about 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, or 145 mg of resveratrol.
The resveratrol may be present in the composition in a highly pure form (for example greater than 98% pure), or alternatively as part of an extract. The extract may be obtained from Polygonum cuspidatum or Polygonum sachalinense, or indeed any other plant or part thereof which contains resveratrol (for example cranberries, blueberries, mulberries, raspberries and certain pine trees). The resveratrol may be present in the composition in the form of a salt or derivative thereof. Suitable derivatives include compounds wherein one or more of the hydroxy groups are derivatised, for example acylated or alkylated.
In accordance with particular embodiments of the invention the amount of proanthocyanidin present in the composition may be between about 15 mg and about 80 mg, or between about 25 mg and about 60 mg, or between about 35 mg and about 55 mg. Alternatively, the composition may comprise about 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, 50 mg, 51 mg, 52 mg, 53 mg, or 54 mg of a proanthocyanidin.
The proanthocyanidin may be present in the composition in a highly pure form (for example greater than 98% pure), or alternatively as part of an extract. The proanthocyanidin may be obtained from grape seed, for example grape seed of Vitis vinifem. Those skilled in the art will appreciate that the proanthocyanidin may also be extracted from many other plants or parts thereof, for example, apples, pine bark, cinnamon, cocoa, grape skin, bilberries, cranberries, chokeberries, blackcurrants, green tea, black tea, Quercus petraea and Quercus robur heartwood. The proanthocyanidin may be present in the composition in the form of a salt or derivative thereof. Suitable derivatives include compounds wherein one or more of the hydroxy groups are derivatised, for example acylated or alkylated.
In accordance with particular embodiments of the invention the amount of grape skin extract present in the composition may be between about 10 mg and about 200 mg, or between about 10 mg and about 100 mg, or between about 20 mg and about 50 mg. Alternatively, the composition may comprise about 25 mg, 30 mg, 35 mg, 40 mg, or 45 mg of grape skin extract.
The grape skin extract may be obtained from any species of the Vitis genus. The species may be Vitis vinifera. Those skilled in the art will appreciate that the grape skin extract may also be obtained from other species of the Vitis genus, including but not limited to Vitis mustangensis, Vitis aestivalis, Vitis riparia, Vitis rotundifolia, and Vitis labrusca.
In accordance with particular embodiments of the invention the amount of vitamin C present in the composition may be between about 25 mg and about 200 mg, or between about 25 mg and about 100 mg, or between about 35 mg and about 65 mg. Alternatively, the composition may comprise about 40 mg, 45 mg, 50 mg, 55 mg, or 60 mg vitamin C.
The oral compositions of the invention may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy. The method may include the step of bringing the components of the oral composition into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing into association the components of the oral composition with a liquid carrier or finely divided solid carrier, or both and then, if necessary, shaping the product into the desired composition.
Compositions suitable for oral administration may be presented as discrete units (i.e. dosage forms) such as gelatine or HP C capsules, cachets or tablets, each containing a predetermined amount each component of the composition as a powder, granules, as a solution or a suspension in an aqueous liquid or a non-aqueous liquid, or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
When the composition is formulated as capsules, the components of the oral composition may be formulated with one or more pharmaceutically acceptable carriers such as starch, lactose, microcrystalline cellulose and/or silicon dioxide. Additional ingredients may include lubricants such as magnesium stearate and/or calcium stearate.
Tablets may be prepared by compression or moulding, optionally with one or more accessory, ingredients. Compressed tablets may be prepared by compressing in a suitable machine the components of the oral composition in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant (for example magnesium stearate or calcium stearate), inert diluent or a surface active/dispersing agent. Moulded tablets may be made by moulding a mixture of the powdered composition moistened with an inert liquid diluent, in a suitable machine. The tablets may optionally be coated, for example, with an enteric coating and may be formulated so as to provide slow or controlled release of the composition therein.
The skilled addressee , will also appreciate that the specific dosing regimen (with respect for example to frequency and duration of administration) to be employed in accordance with embodiments of the invention may be determined on a case-by-case basis. Such determinations are well within the capabilities of those skilled in the art without undue burden or experimentation.
Further, it will be understood that the specific dose level of an oral composition of the invention for any particular individual will depend upon a variety of factors including, for example, the activity of the resveratrol, proanthocyanidin, grape skin and vitamin C employed, the age, body weight, general health and diet of the individual to be treated, the time of administration, rate of excretion, and combination with any other treatment or therapy. Single or multiple daily administrations can be carried out with dose levels. A broad range of doses may be applicable. The present invention contemplates the administration of the oral composition in a food or beverage. The food may be a solid form or a liquid form. Specific examples of the types of foods or beverages include, but are not limited to soft drinks, carbonated drinks, nutritional beverages, fruit beverages, and milk beverages (including a concentrated stock solution of such a beverage and a dry powder for preparation of such a beverage); confectionery such as chewing gum and chocolate; dairy products such as milk, yogurt, butter, and cheese.
In accordance with particular embodiments of the invention the amount of glycolic acid (or hydroxyacetic acid) present in the first topical composition may be between about 10% w/w and about 20% w/w, or more typically between about 12% w/w and about 18% w/w. Alternatively, the first topical composition may comprise about 13% w/w, 14% w/w, 15% w/w, 16% w/w, or 17% w/w glycolic acid.
The glycolic acid may be present in the composition in a highly pure form (for example greater than 98% pure) or alternatively as part of an extract. The extract may be obtained from sugarcane, sugar beets, pineapple, cantaloupe, and unripe grapes, or indeed any other plant or part thereof which glycolic acid. The glycolic acid may be prepared by the reaction of chloroacetic acid with sodium hydroxide followed by re-acidification, however, a person skilled in the art will appreciate that there are other chemical synthesis with which to prepare glycolic acid. Glycolic acid can also be prepared using an enzymatic biochemical process. The glycolic acid may be present in the composition in the form of a salt or derivative thereof.
In accordance with particular embodiments of the invention the amount of Vibrio Alginolyticus ferment filtrate present in the first topical composition may be between about 1% w/w and about 5% w/w, or between about 1 % w/w and about 3% w/w, or between about 1% w/w and about 2% w/w. Alternatively, the composition may comprise about 1.1 % w/w, 1.2% w/w, 1.3% w/w, 1.4% w/w, 1.5% w/w, 1.6% w/w, 1 .7% w/w, 1.8% w/w or 1.9% w/w of Vibrio Alginolyticus ferment filtrate.
The Vibrio Alginolyticus ferment filtrate may be present in the composition in a highly pure form (for example greater than 98% pure), or alternatively as part of an extract. In accordance with particular embodiments of the invention the amount of water lily extract present in the first topical composition may be between about 1% w/w and about 5% w/w, or more typically between about 2% w/w and about 4% w/w. Alternatively, the composition may comprise about 2.5% w/w, 3.0% w/w, or 3.5% w/w of water lily extract.
The water lily extract may be obtained from any species of Nymphaeaceae. The species may be Nymphaea alba. The extract may be derived from the flower of a species of Nymphaeaceae. The water lily extract may be present in the composition in the form of a salt or derivative thereof and may be in the form of a liquid or oil.
In accordance with particular embodiments of the invention the amount of yeast extract present in' the second topical composition may be between about 1% w/w and about. 15% w/w, or more typically between about 2% w/w and about 10% w/w. Alternatively, the second topical composition may comprise about 3% w/w, 4% w/w, 5% w/w, 6% w/w, 7% w/w, 8% w/w, or 9% w/w of yeast extract.
The yeast extract may be obtained from any species of Saccharomyces. The species may be Saccharomyces cerevisiae. The yeast extract may by a polysaccharide extracted from Saccharomyces cerevisiae. The polysaccharide may be a beta-glucan.
In accordance with particular embodiments of the invention the amount of essential fatty acids present in the second topical composition may be between about 0.1% w/w and about 1% w/w, or more typically between about 0.1% w/w and about 0.5% w/w. Alternatively, the second topical composition may comprise about 0.15% w/w, 0.2% w/w, 0.25% w/w, 0.3% w/w,. 0.35% w/w, 0.4% w/w, or 0.45% w/w of essential fatty acids.
The essential fatty acids may be derived from a marine source. The marine source may be vegetal plankton. The essential fatty acids may be omega 3 polyunsaturated fatty acids, for example but not limited to eicosapentaenoic acid and docosahexaenoic acid.
In accordance with particular embodiments of the invention the amount of moisturiser present in the second topical composition may be between about 0.5% w/w and about 7% w/w, or between about 0.5% w/w and about 2.5% w/w, or more typically between about 1.0% w/w and about 2.0% w/w. Alternatively, the second topical composition may comprise about 1.1% w/w, 1.2% w/w, 1.3% w/w, 1.4% w/w, 1.5% w/w, 1.6% w/w, 1.7% w/w, 1.8% w/w or 1.9% w/w of moisturiser.
The moisturiser may be derived from an extract of Sefa vulgaris. The extract may be from the root of Beta vulgaris.
In accordance with particular embodiments of the invention the amount of water lily extract present in the second topical composition may be between about 1% w/w and about 5% w/w, or more typically between about 2% w/w and about 4% w/w. Alternatively, the composition may comprise about 2.5% w/w, 3.0% w/w, or 3.5% w/w of water lily extract.
The water lily extract may be obtained from any species of Nymphaeaceae. The species may be Nymphaea alba. The extract may be derived from the flower of a species of Nymphaeaceae. The water lily extract may be present in the composition in the form of a salt or derivative thereof and may be in the form of a liquid or oil.
In accordance with particular embodiments of the invention the amount of fat-soluble vitamins present in the second topical composition may be between about 0.1% w/w and about 5% w/w, or more typically between about 0.1% w/w and about 3.5% w/w. Alternatively, the second topical composition may comprise about 0.5% w/w, 1.0% w/w, 1.5% w/w, 2.0% w/w, 2.5% w/w or 3.0% w/w of fat-soluble vitamins.
The fat-soluble vitamins may comprise vitamin E, vitamin Ki and vitamin A. The vitamin E may be present as tocopheryl acetate, the vitamin Ki may be present as phytonadione, and the vitamin A may be present as retinyl palmitate. Those skilled in the art will appreciate that the fat-soluble vitamins may be present in the second topical composition in the form of other salt or derivative thereof.
In accordance with particular embodiments of the invention the amount of water-soluble vitamins present in the second topical composition may be between about 0.1% w/w and about 5% w/w, or more typically between about 0.1% w/w and about 3.5% w/w. Alternatively, the second topical composition may comprise about 0.5% w/w, 1.0% w/w, 1.5% w/w, 2.0% w/w, 2.5% w/w or 3.0% w/w of water-soluble vitamins. The water-soluble vitamins may comprise vitamin C, vitamin B3, vitamin B5 and vitamin B6. The vitamin C may be present as sodium ascorbyl phosphate, the vitamin B3 may be present as niacinamide, the vitamin B5 may be present as calcium pantothenate, and the vitamin B6 may be present as pyndoxine hydrochloride. Those skilled in the art will appreciate that the water-soluble vitamins may be present in the second topical composition in the form of other salt or derivative thereof.
The topical formulations of the present invention typically comprise the components of the invention together with one or more acceptable carriers, and optionally any other therapeutic ingredients. Formulations suitable for topical administration may be in any suitable form, formulated for example as liminents, lotions, creams, . gels, ointments or pastes. Examples of pharmaceutically acceptable carriers or diluents are demineralised or distilled water; saline solution; vegetable based oils such as peanut oil, safflower oil, olive oil, cottonseed oil, maize oil, sesame oil, arachis oil or coconut oil; silicone oils, including polysiloxanes, such as methyl polysiloxane, phenyl polysiloxane and methylphenyl polysolpoxane; volatile silicones; mineral oils such as liquid paraffin, soft paraffin or squalane; cellulose derivatives such as methyl cellulose, ethyl cellulose, carboxymethylcellulose, sodium carboxymethylcellulose or hydroxypropylmethylcellulose; lower alkanols, for example ethanol or iso-propanol; lower aralkanols; lower polyalkylene glycols or lower alkylene glycols, for example polyethylene glycol, polypropylene glycol, ethylene glycol, propylene glycol, 1 ,3-butylene glycol or glycerin; fatty acid esters such as isopropyl palmitate, isopropyl myristate or ethyl oleate; polyvinylpyrridone; agar; carrageenan; gum tragacanth or gum acacia, and petroleum jelly. Typically, the carrier or carriers will form from 10% to 99.9% by weight of the compositions.
Lotions according to the present invention include those suitable for application to the skin. Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturiser such as glycerol, or oil such as castor oil or arachis oil.
Creams, ointments or pastes according to the present invention are semi-solid formulations of the agents for external application. They may be made by mixing the components in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with a . greasy or non-greasy basis. The basis may comprise hydrocarbons such as hard, soft or liquid glycerin, paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as corn, arachis, castor or olive oil; wool fat or its derivatives, or a fatty acid such as stearic or oleic acid together with an alcohol such as propylene glycol or macrogols.
The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.
The present invention will now be described with reference to the following specific examples, which should not be construed as in any way limiting the scope of the invention.
Examples
Example 1 -Oral and topical compositions
By way of example only a suitable compositions for use in accordance with the invention are outlined below. The following is to be construed as merely an illustrative example of a composition and not as a limitation of the scope of the present invention in any way.
A typical composition for oral administration is outlined below:
Each capsule or tablet comprises:
Herbal extracts equiv. to dry:
Polygonum cuspidatum (giant knotweed) root
equiv. resveratrol
Vitis vinifera (grape) seed
equiv. proanthocyanidins 47.5 mg
Vitis vinifera (grape) skin 30 mg
Nutrients:
Ascorbic acid (vitamin C) 50 mg
Quercetin 40 mg
Dosage: 1 capsule or tablet once to three times daily.
A typical first composition for topical administration is outlined below:
• Glycolic acid 15% w/w
• Vibrio Alginolyticus ferment filtrate and
butylene glycol 1.5% w/w
• Nymphea alba flower extract 3% w/w
Dosage:
A thin layer of the first topical composition is administered to the skin and left for 10 mins. The first topical composition is then removed with warm water.
A typical second composition for topical administration is outlined below:
• Saccharomyces extract 2-10% w/w
• Vegetal plankton extract 0.2% w/w
· Hydrolysed com starch and
Beta Vulgaris root extract 1.5%w/w
• Nymphea alba flower extract 3% w/w
• Water-soluble vitamins blend
(vitamin E, vitamin Ki & vitamin A) 0.5-2%
· Fat-soluble vitamins
(vitamin C, vitamin B3, vitamin B5 & vitamin B6) 0.5-3%
Dosage:
After using the first topical composition a thin layer of the second topical composition is administered to the skin and left on overnight.

Claims

The claims defining the invention are as follows:
1. A method for improving the health of the skin of a subject, the method comprising administering to a subject an oral composition comprising resveratrol, a proanthocyanidin, grape skin extract and vitamin C; a first topical composition comprising glycolic acid, a Vibrio Alginolyticus ferment filtrate and a water lily extract; and a second topical composition comprising a yeast extract, essential fatty acids, moisturiser, a water lily extract, water-soluble vitamins and fat-soluble vitamins.
2. A method according to claim 1, wherein the first topical composition is administered to the skin before the second topical composition.
3. A method according to claim 2, wherein the first topical composition is left on the skin for approximately 10 min and then removed.
4. A method according to any one claims 1 to 3, wherein the grape skin extract is obtained from Vitis vinifera.
5. A method according to any one of claims 1 to 4, wherein the amount of grape skin extract in the composition is from about 10 mg to about 200 mg.
6. A method according to any one of claims 1 to 5, wherein the amount of grape skin extract in the composition is about 30 mg.
7. A method according to any one of claims 1 to 6, wherein the amount of resveratrol in the composition is from about 25 mg to about 300 mg.
8. A method according to any one of claims 1 to 7, wherein the amount of resveratrol in the composition is about 100 mg.
9. A method according to any one of claims 1 to 8, wherein the resveratrol is present in the composition as an extract.
10. A method according to claim 9, wherein the extract is obtained from Polygonum cuspidatum or Polygonum sachalinense.
11. A method according to any one of claims 1 to 10, wherein the amount of the proanthocyanidin in the composition is from about 15 mg to about 80 mg.
5
12. A method according to any one of claims 1 to 11 , wherein the amount of the proanthocyanidin in the composition is about 47.5 mg.
13. A method according to any one of claims 1 to 12, wherein the proanthocyanidin is present * io in the composition as an extract.
14. A method according to claim 13, wherein the extract is obtained from grape seed.
15. A method according to claim 14, wherein the grape is Vitis vinifera.
16. A method according to any one of claims 1 to 15, wherein the amount of the vitamin C in the composition is from about 25 mg to about 200 mg.
17. A method according to any one of claims 1 to 16, wherein the amount of the vitamin C in 20 the composition is about 50 mg.
18. A method according to any one of claims 1 to 17, wherein the oral composition further comprises quercetin.
25 19. A method according to claim 18, wherein the amount of quercetin in the oral composition is from about 10 mg to about 100 mg.
20. A method according to claim 18 or claim 19, wherein the amount of quercetin in the oral composition is about 40 mg.
30
21. A method according to any one of claims 1. to 20, wherein the oral composition further comprises one or more pharmaceutically acceptable excipient, diluent or adjuvant.
22. A method according to any one of claims 1 to 21 , wherein the oral composition is in the form of a unit dosage form.
23. A method according to any one of claim 22, wherein the unit dosage form is a tablet, a capsule or a caplet.
24. A method according to any one of claim 22 or claim 23, wherein between 1 and 5 unit dosage forms are administered per day.
25. A method according to any one of claims 1 to 20, wherein the oral composition is in the form of a food stuff or beverage. · J .' ■
26. A method according to any one of claims 1 to 25, wherein the amount of glycolic acid in the first topical composition is between about 10% w/w and about 20% w/w.
27. A method according to any one of claims 1 to 26, wherein the amount of glycolic acid in the first topical composition is about 15% w/w.
28. A method according to any one of claims 1 to 27, wherein the amount of Vibrio Alginolyticus ferment filtrate in the first topical composition is between about 1% w/w and about 5% w/w.
29. A method according to any one of claims 1 to 28, wherein the amount of Vibrio Alginolyticus ferment filtrate present in the first topical composition is about 1.5% w/w.
30. A method according to any one of claims 1 to 29, wherein the amount of water lily extract in the first topical composition is about 3% w/w.
31. A method according to any one of claims 1 to 30, wherein the water lily extract in the first topical composition is obtained from Nymphaea alba.
32. A method according to any one of claims 1 to 31 , wherein the amount of yeast extract in the second topical composition is between about 1 % w/w and about 15% w/w.
33. A method according to any one of claims 1 to 32, wherein the amount of yeast extract in the second topical composition is 5% w/w.
34. A method according to any one of claims 1 to 33, wherein the yeast extract in the second topical composition is obtained from a species of Saccharomyces.
5 '
35. A method according to claim 34, wherein the species is Saccharomyces cerevisiae.
36. A method according to any one of claims 1 to 35, wherein the amount of essential fatty acids in the second topical composition is about 0.2% w/w.
10
37. A method according to any one of claims 1 to 36, wherein the essential fatty acids in the second topical composition are derived from a marine source.
38. A method according to any one of claims 1 to 37, wherein the essential fatty acids i s comprise eicosapentaenoic acid and docosahexaenoic acid.
39. A method according to any one of claims 1 to 38, wherein the amount of moisturiser present in the second topical composition is between about 0.5% w/w and about 7% w/w.
20 40. A method according to any one of claims 1 to 39, wherein the amount of moisturiser present in the second topical composition is 1.5% w/w.
41. A method according to any one of claims 1 to 40, wherein the moisturiser is obtained from Beta vulgaris.
25
42. A method according to any. one of claims 1 to 41, wherein moisturiser is obtained from the root of Beta vulgaris.
43. A method according to any one of claims 1 to 42, wherein the amount of water lily extract in 30 the second topical composition is about 3% w/w.
44. A method according to any one of claims- 1 to 43, wherein the water lily extract in the second topical composition is obtained from Nymphaea alba.
45. A method according to any one of claims 1 to 44, wherein the amount of fat-soluble vitamins present in the second topical composition is between about 0.1% w/w and about 5% w/w.
46. A method according to any one of claims 1 to 45, wherein the amount of fat-soluble vitamins present in the second topical composition is between about 0.5% w/w and about 2% w/w.
47. A method according to any one of claims 1 to 46, wherein the present in the first topical composition fat-soluble vitamins comprise vitamin E, vitamin Ki and vitamin A.
48. A method according to any one of claims 1 to 47, wherein the amount of water-soluble vitamins present in the second topical composition is between about 0.1% w/w and about 5% w/w.
49. A method according to any one of claims 1 to 48, wherein the amount of water-soluble vitamins present in the second topical composition is between about 0.5% w/w and about 3% w/w.
50. A method according to any one of claims 1 to 49, wherein the water-soluble vitamins present in the second topical composition comprise vitamin C, vitamin B3, vitamin B5 and vitamin B6.
PCT/AU2011/000452 2010-04-20 2011-04-20 Combined method for improving the health of skin WO2011130788A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011242403A AU2011242403A1 (en) 2010-04-20 2011-04-20 Combined method for improving the health of skin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2010901652 2010-04-20
AU2010901652A AU2010901652A0 (en) 2010-04-20 Combined method for improving the health of skin

Publications (1)

Publication Number Publication Date
WO2011130788A1 true WO2011130788A1 (en) 2011-10-27

Family

ID=44833554

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2011/000452 WO2011130788A1 (en) 2010-04-20 2011-04-20 Combined method for improving the health of skin

Country Status (2)

Country Link
AU (1) AU2011242403A1 (en)
WO (1) WO2011130788A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806769B2 (en) 2016-03-31 2020-10-20 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US10874700B2 (en) 2016-03-31 2020-12-29 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
US11564879B2 (en) 2016-11-23 2023-01-31 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
US12102707B2 (en) 2019-06-28 2024-10-01 The Procter & Gamble Company Skin care composition

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3120188B3 (en) * 2021-02-26 2023-09-22 Activinside Composition comprising an extract of Vitis vinifera, vitamin C and probiotics to fight against skin aging

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2385768A (en) * 2002-01-31 2003-09-03 Dodson & Horrell Ltd Animal feed supplement
US20040001817A1 (en) * 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
CA2546464A1 (en) * 2005-05-04 2006-11-04 Richard Wachsberg Sequential application of oral and topical formulations for treating wrinkles and other damage to skin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2385768A (en) * 2002-01-31 2003-09-03 Dodson & Horrell Ltd Animal feed supplement
US20040001817A1 (en) * 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
CA2546464A1 (en) * 2005-05-04 2006-11-04 Richard Wachsberg Sequential application of oral and topical formulations for treating wrinkles and other damage to skin

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10806769B2 (en) 2016-03-31 2020-10-20 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US10874700B2 (en) 2016-03-31 2020-12-29 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
US11633451B2 (en) 2016-03-31 2023-04-25 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US11998575B2 (en) 2016-03-31 2024-06-04 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
US11564879B2 (en) 2016-11-23 2023-01-31 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
US12102707B2 (en) 2019-06-28 2024-10-01 The Procter & Gamble Company Skin care composition

Also Published As

Publication number Publication date
AU2011242403A1 (en) 2012-12-06

Similar Documents

Publication Publication Date Title
EP2654766B1 (en) Extract of the pulp and/or peel of avocado rich in polyphenols and cosmetic, dermatologic or nutraceutic compositions comprising thereof
EP2459161B1 (en) Cosmetic composition for the treatment of acne comprising a peptide extract of schizandra sphenanthera
EP2285343B1 (en) Use of a wolfberry extract, for maintaining and/or restoring the tonus and/or firmness of the skin
KR102110902B1 (en) Composition for anti-oxidation, anti-inflammation, anti-diabetes, whitening, anti-wrinkle, or anti-gout comprising extract of Ruby-S apple peel
FR2919501A1 (en) USE OF HESPERIDINE OR ONE OF ITS DERIVATIVES FOR THE PREVENTION AND / OR TREATMENT OF RELEASED SKIN
WO2011130788A1 (en) Combined method for improving the health of skin
KR20130024025A (en) A anti-inflammatory or skin moisturizing composition containing fermented plant extracts as an active ingredient
JP5617110B2 (en) Oral hair growth promoter
KR101889793B1 (en) Composition for prevention of hair loss or for promoting hair growth comprising a marine animal fermentation
KR20200052867A (en) Composition for anti-inflammation, anti-diabetes, whitening, or inhibition of gout comprising extract of Ruby-S apple peel as an active ingredient
FR2930155A1 (en) USE OF A BAY EXTRACT, AND MORE PARTICULARLY WOLFBERRY, AS ANTI-POLLUTION AGENT
US20110123463A1 (en) Topical compositions
JP2023118853A (en) Anti-aging composition, anti-aging skin cosmetics and anti-aging food and drink
CN114209632B (en) Pre-washing hair-fixing essential oil
JP2017178914A (en) Composition for improving and enhancing brain function
JP7424606B2 (en) beauty composition
AU2013100431B4 (en) Combined method for improving the health of skin
KR102144677B1 (en) Composition for anti-oxidation, anti-inflammation, or anti-wrinkle comprising extract of Greenball apple peel
JP2019182863A (en) Skin firmness or moisture improving composition
JP4413272B1 (en) Hyaluronic acid production promoter
KR20140115228A (en) Composition for prevention or treatment of hair loss comprising oriental herbal extracts
KR102429214B1 (en) A composition for stimulating growth of hairs contaning natural complex extracts
AU2011242402A1 (en) Method for improving the health of skin
EP1879539B1 (en) Skin protective composition based on araucaria grain extracts
AU2013100430A4 (en) Method for improving the health of skin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11771400

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2011242403

Country of ref document: AU

Date of ref document: 20110420

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 11771400

Country of ref document: EP

Kind code of ref document: A1